Combining GLP-1 receptor agonists (GLP-1RAs) with lifestyle modifications results in significantly greater weight loss and improved cardiometabolic biomarkers compared to lifestyle modifications alone in adults with overweight or obesity.

Lifestyle modification combined with GLP-1RAs results in a significant mean weight loss of 7.13 kg compared with control groups (MD: −7.13 kg, 95% CI: −9.02, −5.24, P < 0.001). Significant improvements were also observed in other body composition parameters and cardiometabolic biomarkers, including waist circumference (MD: −5.74 cm, 95% CI: −7.17, −4.31, P < 0.001), lean mass (MD: −1.29 kg, 95% CI: −2.17, −0.41, P = 0.004), fat mass (MD: −2.93 kg, 95% CI: −4.70, −1.12, P = 0.001), systolic blood pressure (MD: −3.99 mmHg, 95% CI: −5.66, −2.33, P < 0.001), diastolic blood pressure (MD: −1.11 mmHg, 95% CI: −1.71, −0.42, P = 0.002), glycated hemoglobin (MD: −0.31%, 95% CI: −0.47, −0.15, P < 0.001), fasting blood glucose (MD: −6.51 mg/dL, 95% CI: −7.31, −4.71, P = 0.004), total cholesterol (MD: −5.85 mg/dL, 95% CI: −9.78, −1.91, P = 0.004), triglycerides (MD: −13.44 mg/dL, 95% CI: −20.38, −6.50, P < 0.001), low-density lipoprotein cholesterol (MD: −4.78 mg/dL, 95% CI: −7.35, −2.22, P = 0.003)